This patent covers induced pluripotent stem cells (iPSCs) with a specific gene knock out of the adenosine A2A receptor (A2AR). This receptor is critical for inhibiting immune cell function in the tumour microenvironment of solid tumours.

Adenosine, which is found in high levels in solid tumours, suppresses the activity of immune cells like natural killer (NK) cells. Therefore, removing the A2A receptor from Cartherics’ NK cells should help these cells remain active in the tumour microenvironment.

This patent secures a proprietary position for multiple development candidates in Cartherics’ pipeline and strengthens the company’s already robust IP position. With a large and growing market, China’s patent protection system offers substantial commercial value for effective patents.